WO2005065657A3 - Solid compositions of low-solubility drugs and poloxamers - Google Patents

Solid compositions of low-solubility drugs and poloxamers Download PDF

Info

Publication number
WO2005065657A3
WO2005065657A3 PCT/IB2004/004287 IB2004004287W WO2005065657A3 WO 2005065657 A3 WO2005065657 A3 WO 2005065657A3 IB 2004004287 W IB2004004287 W IB 2004004287W WO 2005065657 A3 WO2005065657 A3 WO 2005065657A3
Authority
WO
WIPO (PCT)
Prior art keywords
poloxamers
low
solid compositions
solubility drugs
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/004287
Other languages
French (fr)
Other versions
WO2005065657A2 (en
Inventor
Daniel Tod Smithey
Warren Kenyon Miller
Dwayne Thomas Friesen
Walter Christian Babcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to US10/596,876 priority Critical patent/US8974823B2/en
Priority to BRPI0418330-4A priority patent/BRPI0418330A/en
Priority to CA002548376A priority patent/CA2548376A1/en
Priority to JP2006546397A priority patent/JP2007517016A/en
Priority to EP04806454A priority patent/EP1701704A2/en
Publication of WO2005065657A2 publication Critical patent/WO2005065657A2/en
Publication of WO2005065657A3 publication Critical patent/WO2005065657A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed.
PCT/IB2004/004287 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers Ceased WO2005065657A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/596,876 US8974823B2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers
BRPI0418330-4A BRPI0418330A (en) 2003-12-31 2004-12-20 solid compositions of low solubility drugs and poloxamers
CA002548376A CA2548376A1 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers
JP2006546397A JP2007517016A (en) 2003-12-31 2004-12-20 Solid composition of low solubility drug and poloxamer
EP04806454A EP1701704A2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53383603P 2003-12-31 2003-12-31
US60/533,836 2003-12-31

Publications (2)

Publication Number Publication Date
WO2005065657A2 WO2005065657A2 (en) 2005-07-21
WO2005065657A3 true WO2005065657A3 (en) 2006-06-22

Family

ID=34748969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/004287 Ceased WO2005065657A2 (en) 2003-12-31 2004-12-20 Solid compositions of low-solubility drugs and poloxamers

Country Status (6)

Country Link
US (1) US8974823B2 (en)
EP (1) EP1701704A2 (en)
JP (1) JP2007517016A (en)
BR (1) BRPI0418330A (en)
CA (1) CA2548376A1 (en)
WO (1) WO2005065657A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005047561A1 (en) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
WO2008119659A2 (en) * 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Pharmaceutical composition and process
SI2200588T1 (en) 2007-09-25 2019-08-30 Solubest Ltd. Compositions comprising lipophilic active compounds and process for their preparation
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
ES2801678T3 (en) * 2010-07-12 2021-01-12 Salix Pharmaceuticals Inc Rifaximin formulations and their uses
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
AR088570A1 (en) * 2011-10-28 2014-06-18 Celgene Avilomics Res Inc METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
JP6138904B2 (en) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー Nonlinear multiblock copolymer drug conjugates for delivery of active agents
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR102310775B1 (en) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. Pharmaceutical nanoparticles showing improved mucosal transport
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) * 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
JP5934677B2 (en) * 2013-06-18 2016-06-15 住友ゴム工業株式会社 Rubber composition for tire and pneumatic tire
JP5946798B2 (en) * 2013-06-18 2016-07-06 住友ゴム工業株式会社 Rubber composition for tire and pneumatic tire
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6010060B2 (en) * 2014-02-21 2016-10-19 住友ゴム工業株式会社 Rubber composition for tire and pneumatic tire
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
RU2639819C2 (en) * 2014-12-30 2017-12-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Composition inhibiting telomerase
CN107635545A (en) 2015-01-27 2018-01-26 约翰霍普金斯大学 For strengthening the hypotonic aqueogel of the conveying of activating agent at mucomembranous surface
PT3518924T (en) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Solid dispersion forms of rifaximin
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089835A2 (en) * 2001-05-03 2002-11-14 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003074026A1 (en) * 2002-03-07 2003-09-12 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
ATE232087T1 (en) 1997-10-27 2003-02-15 Merck Patent Gmbh SOLID SOLUTIONS AND DISPERSIONS OF A POORLY WATER-SOLUBLE ACTIVE SUBSTANCE
EP1103258A1 (en) 1998-07-22 2001-05-30 Yamanouchi Pharmaceutical Co. Ltd. Solid preparation containing sparingly soluble nsaids
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DK1227797T3 (en) 1999-11-12 2005-05-30 Abbott Lab Pharmaceutical solid dispersion formulations
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
SK12682001A3 (en) * 1999-12-08 2002-07-02 Pharmacia Corporation, Corporate Patent Department Solid-state form of celecoxib having enhanced bioavailability
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
WO2001054667A1 (en) 2000-01-28 2001-08-02 Smithkline Beecham Corporation Electrospun pharmaceutical compositions
AR027656A1 (en) * 2000-03-16 2003-04-09 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF GLUCOGENO-FOSFORILASA
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
CA2407027C (en) 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0015239D0 (en) 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
DE10038571A1 (en) 2000-08-03 2002-02-14 Knoll Ag Compositions and dosage forms for use in the oral cavity in the treatment of mycoses
KR20020014570A (en) 2000-08-18 2002-02-25 김충섭 Process for Preparing Amorphous-type Ipriflavone by Solid-Dispersion
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089835A2 (en) * 2001-05-03 2002-11-14 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003074026A1 (en) * 2002-03-07 2003-09-12 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers

Also Published As

Publication number Publication date
CA2548376A1 (en) 2005-07-21
JP2007517016A (en) 2007-06-28
US8974823B2 (en) 2015-03-10
BRPI0418330A (en) 2007-05-02
WO2005065657A2 (en) 2005-07-21
EP1701704A2 (en) 2006-09-20
US20070141143A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
WO2005041924A3 (en) Administration of levodopa and carbidopa
EP1513825A4 (en) ANTI-TUBERCULOUS DRUG: COMPOSITIONS AND METHODS
HUE040046T2 (en) Methods of administering pharmaceutical compositions and drugs
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
EP1391200A4 (en) DRUG PREPARATIONS
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
IL198687A0 (en) Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
MXPA05013147A (en) Solid pharmaceutical preparation.
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
UA88300C2 (en) Hydrogel interferon formulations
IL164217A0 (en) Pharmaceutical compositions containing water-soluble propofol and methods of administering same
EA200401227A1 (en) DELIVERY DELIVERY SYSTEM WITH CONTROLLED DELAY, INCLUDING PRAVASTATIN
WO2006097535A3 (en) Peptide agonists of the glucagon family with secretin like activity
WO2004091591A3 (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
ITRM20030363A1 (en) COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM.
WO2008081829A1 (en) Aminoalkylmethacrylate copolymer e for maintaining solubility of poorly water-soluble drug
WO2007005941A3 (en) Liver targeted conjugates
WO2003068157A3 (en) Kinase inhibitors and methods of use thereof
WO2005074925A8 (en) Compositions substantially free of galactomannan containing piperacillin and tazobactam
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
EA200801614A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MONTELUKAST
IL172096A0 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004806454

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2548376

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006546397

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/007625

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2004806454

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007141143

Country of ref document: US

Ref document number: 10596876

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0418330

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10596876

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004806454

Country of ref document: EP